AXSM - Axsome's Strategy on Payer Coverage Slowly Pays Off Depression Drug Sales Show Growth | Benzinga
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q3 revenues of $57.8 million, up 244% Y/Y, beating the consensus of $54.75 million.
Auvelity (oral antidepressant) net product sales were $37.7 million, representing a 36% sequential increase versus the second quarter of 2023.
Approximately 69,000 prescriptions were reported for Auvelity in Q3, up 30% Q/Q.
The previously announced expansion of the Auvelity sales force from 162 to 260 representatives is underway and expected to be completed in Q4 FY23.
Also Read: FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says.
Sunosi (sleep ...